A Phase 3 interventional study of Everolimus and Tacrolimus in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C virus (HCV), hepatocellular carcinoma (HCC), and short/long-term implications. Then efficacy and safety of a calcineurin inhibitor (CNI)-withdrawal regimen was evaluated in comparison with a CNI-minimization regimen.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria at Baseline:
Inclusion criteria at Randomization:
Exclusion criteria at Baseline:
Exclusion criteria at Randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
Drug: Everolimus · Drug: Tacrolimus
At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
Drug: Everolimus · Drug: Tacrolimus
Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR)
Renal function was assessed by eGFR using the MDRD-4 formula at 12 months after transplant: eGFR = 186.3 \* (serum creatinine)-1.154 \* age-0.203 \* (0.742 for women) \* (1.21 if African American) where serum creatinine was in mg/dL and age in years.
Time frame: At 12 months post-transplant
Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D)
Participants were assessed for tBPAR, AR, GL or death. For all suspected rejection episodes, regardless of initiation of anti-rejection treatment, a liver biopsy was to be performed preferably within 24 hours, latest within 48 hours whenever clinically possible. A treated biopsy proven acute rejection was considered an episode of acute rejection when demonstrated by local pathology reading with a rejection activity index of at least 3 or greater of acute rejection index and when treated with anti-rejection therapy. The allograft was considered lost on the day the subject was re-transplanted or died due to liver failure.
Time frame: At 12 and 18 months post-transplant
Change From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant
Blood samples were collected to assess serum creatinine.
Time frame: baseline, 12 months post-transplant
68 participants completed run-in but only 50 decided to move forward to randomization.
| Milestone | Group A (Tacrolimus Elimination Arm) | Group B (Tacrolimus Minimization Arm) | Total Enrolled at run-in |
|---|---|---|---|
| Started | 0 | 0 | 78 |
| Completed | 0 | 0 | 68 |
| Not completed | 0 | 0 | 10 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Administrative problems | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 |
| Milestone | Group A (Tacrolimus Elimination Arm) | Group B (Tacrolimus Minimization Arm) | Total Enrolled at run-in |
|---|---|---|---|
| Started | 24 | 26 | 0 |
| Completed | 22 | 26 | 0 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
Renal function was assessed by eGFR using the MDRD-4 formula at 12 months after transplant: eGFR = 186.3 \* (serum creatinine)-1.154 \* age-0.203 \* (0.742 for women) \* (1.21 if African American) where serum creatinine was in mg/dL and age in years.
| mL/min/1.73m^2 | Group A (Tacrolimus Elimination Arm) | Group B (Tacrolimus Minimization Arm) |
|---|---|---|
| Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) | 85.50 ± 3.97 | 80.26 ± 3.87 |
Participants were assessed for tBPAR, AR, GL or death. For all suspected rejection episodes, regardless of initiation of anti-rejection treatment, a liver biopsy was to be performed preferably within 24 hours, latest within 48 hours whenever clinically possible. A treated biopsy proven acute rejection was considered an episode of acute rejection when demonstrated by local pathology reading with a rejection activity index of at least 3 or greater of acute rejection index and when treated with anti-rejection therapy. The allograft was considered lost on the day the subject was re-transplanted or died due to liver failure.
| Participants | Group A (Tacrolimus Elimination Arm) | Group B (Tacrolimus Minimization Arm) |
|---|---|---|
| tBPAR, 12 months | 2 | 1 |
| AR, 12 months | 2 | 1 |
| GL, 12 months | 0 | 0 |
| Death, 12 months | 1 | 0 |
| tBPAR, 18 months | 2 | 1 |
| AR, 18 months | 2 | 1 |
| GL, 18 months | 0 | 0 |
| Death, 18 months | 1 | 1 |
Blood samples were collected to assess serum creatinine.
| mg/dL | Group A (Tacrolimus Elimination Arm) | Group B (Tacrolimus Minimization Arm) |
|---|---|---|
| Change From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant | -0.11 ± 0.04 | -0.05 ± 0.03 |
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Population Total | — | 25/78 (32.1%) | 57/78 (73.1%) |
| Run-in Population Tacrolimus Elimination | — | 4/24 (16.7%) | 20/24 (83.3%) |
| Run-in Population Tacrolimus Minimization | — | 9/26 (34.6%) | 21/26 (80.8%) |
| Randomization Treatment Period Tacrolimus Elimination | — | 4/24 (16.7%) | 16/24 (66.7%) |
| Randomization Treatment Period Tacrolimus Minimization | — | 9/26 (34.6%) | 15/26 (57.7%) |
| Event | Run-in Population Total | Run-in Population Tacrolimus Elimination | Run-in Population Tacrolimus Minimization | Randomization Treatment Period Tacrolimus Elimination | Randomization Treatment Period Tacrolimus Minimization |
|---|---|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 7/78 | 2/24 | 1/26 | 0/24 | 0/26 |
| CholangitisHepatobiliary disorders | 3/78 | 2/24 | 0/26 | 0/24 | 0/26 |
| LeukopeniaBlood and lymphatic system disorders | 0/78 | 0/24 | 0/26 | 0/24 | 2/26 |
| PyrexiaGeneral disorders | 5/78 | 0/24 | 2/26 | 1/24 | 1/26 |
| Blood bilirubin increasedInvestigations | 6/78 | 1/24 | 2/26 | 0/24 | 0/26 |
| Alanine aminotransferase increasedInvestigations | 5/78 | 1/24 | 1/26 | 1/24 | 0/26 |
| PericarditisCardiac disorders | 0/78 | 0/24 | 0/26 | 1/24 | 0/26 |
| AscitesGastrointestinal disorders | 1/78 | 1/24 | 0/26 | 0/24 | 0/26 |
| Bile duct stenosisHepatobiliary disorders | 0/78 | 0/24 | 0/26 | 1/24 | 0/26 |
| Liver disorderHepatobiliary disorders | 1/78 | 1/24 | 0/26 | 0/24 | 0/26 |
| Event | Run-in Population Total | Run-in Population Tacrolimus Elimination | Run-in Population Tacrolimus Minimization | Randomization Treatment Period Tacrolimus Elimination | Randomization Treatment Period Tacrolimus Minimization |
|---|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 3/78 | 0/24 | 1/26 | 5/24 | 1/26 |
| AnaemiaBlood and lymphatic system disorders | 5/78 | 0/24 | 3/26 | 0/24 | 5/26 |
| PyrexiaGeneral disorders | 14/78 | 4/24 | 4/26 | 3/24 | 4/26 |
| AstheniaGeneral disorders | 7/78 | 4/24 | 1/26 | 0/24 | 0/26 |
| Blood alkaline phosphatase increasedInvestigations | 3/78 | 0/24 | 1/26 | 4/24 | 0/26 |
| Gamma-glutamyltransferase increasedInvestigations | 4/78 | 1/24 | 2/26 | 4/24 | 2/26 |
| Transaminases increasedInvestigations | 9/78 | 4/24 | 4/26 | 2/24 | 2/26 |
| LeukopeniaBlood and lymphatic system disorders | 6/78 | 0/24 | 4/26 | 1/24 | 2/26 |
| Diabetes mellitusMetabolism and nutrition disorders | 6/78 | 1/24 | 4/26 | 1/24 | 1/26 |
| NauseaGastrointestinal disorders | 8/78 | 3/24 | 2/26 | 0/24 | 1/26 |
Run-in Population: all consented and everolimus-treated patients who entered the run-in treatment period. All 78 enrolled patients were included in the run-in treatment period. Treatment started at the randomization period.
| Age, Continuous(Years) | Total Enrolled at run-in |
|---|---|
| Mean | 53.73 ± 9.69 |
| Sex: Female, Male(Participants) | Total Enrolled at run-in |
|---|---|
| Female | 19 |
| Male | 59 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Mar 2014 to primary completion in Sep 2016, 30 months.
Results were first posted in Feb 2019, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Everolimus · Tacrolimus